nach oben

Erschienen in:

01.08.2014 | Review Article

Management options for established chemotherapy-induced peripheral neuropathy

verfasst von: Deirdre R. Pachman, James C. Watson, Maryam B. Lustberg, Nina D. Wagner-Johnston, Alexandre Chan, Larry Broadfield, Yin Ting Cheung, Christopher Steer, Dawn J. Storey, Kavita D. Chandwani, Judith Paice, Pascal Jean-Pierre, Jeong Oh, Jayesh Kamath, Marie Fallon, Herwig Strik, Susanne Koeppen, Charles L. Loprinzi

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a variety of chemotherapeutic agents. Clinicians are cognizant of the negative impact of CIPN on cancer treatment outcomes and patients’ psychosocial functioning and quality of life. In an attempt to alleviate this problem, clinicians and patients try various therapeutic interventions, despite limited evidence to support efficacy of these treatments. The rationale for such use is mostly based on the evidence for the treatment options in non-CIPN peripheral neuropathy syndromes, as this area is more robustly studied than is CIPN treatment. In this manuscript, we examine the existing evidence for both CIPN and non-CIPN treatments and develop a summary of the best available evidence with the aim of developing a practical approach to the treatment of CIPN, based on available literature and clinical practice experience.

Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081–3094PubMedCrossRef

Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125:767–774PubMedCrossRef

Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16:708–716PubMedCentralPubMedCrossRef

Gewandter JS, Fan L, Magnuson A, Mustian K, Peppone L, Heckler C, Hopkins J, Tejani M, Morrow GR, Mohile SG (2013) Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer 21:2059–2066PubMedCentralPubMedCrossRef

Tofthagen C, Overcash J, Kip K (2012) Falls in persons with chemotherapy-induced peripheral neuropathy supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 20: 583–589

Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB (2012) Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848

Dworkin RH, Turk DC, Basch E, Berger A, Cleeland C, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Markman J, Porter L, Raja SN, Ross E, Todd K, Wallace M, Woolf CJ (2011) Considerations for extrapolating evidence of acute and chronic pain analgesic efficacy. Pain 152:1705–1708PubMedCrossRef

Boyette-Davis JA, Cata JP, Zhang H, Driver LC, Wendelschafer-Crabb G, Kennedy WR, Dougherty PM (2011) Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J Pain Off J Am Pain Soc 12:1017–1024CrossRef

Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109:132–142PubMedCrossRef

10.

Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB, Loprinzi CL (2012) The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20:625–632PubMedCentralPubMedCrossRef

11.

Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Lin CC, Yen CC, Tzeng CH, Wang WS, Chiang HL, Teng CJ, Teng HW (2011) Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer

12.

Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA J Am Med Assoc 309:1359–1367CrossRef

13.

Durand JP, Alexandre J, Guillevin L, Goldwasser F (2005) Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 16:587–591PubMedCrossRef

14.

Durand JP, Goldwasser F (2002) Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. Anticancer Drugs 13:777–780PubMedCrossRef

15.

Ozdogan MSM, Bozcuk HS et al (2004) Venlafaxine for treatment of chemotherapy-induced neuropathic pain. Turk J Cancer 34:110–112

16.

Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ, Soori GS, Tirona MT, Rowland KM Jr, Stella PJ, Johnson JA (2002) Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 98:195–203PubMedCrossRef

17.

Kautio AL, Haanpaa M, Saarto T, Kalso E (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 35:31–39PubMedCrossRef

18.

Mariani G et al. (2000) Oxaliplatin induced neuropathy: could gabapentin be the answer? Proc Am Soc Clin Oncol 19 (abstract 2397)

19.

Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110–2118PubMedCrossRef

20.

Saif MW, Syrigos K, Kaley K, Isufi I (2010) Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res 30:2927–2933PubMed

21.

Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, Gross HM, Renno SI, Nashawaty M, Loprinzi CL (2008) Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 112:2802–2808PubMedCrossRef

22.

Liu YC, Wang WS (2012) Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. Cancer 118:1718–1725PubMedCrossRef

23.

Cartoni C, Brunetti GA, Federico V, Efficace F, Grammatico S, Tendas A, Scaramucci L, Cupelli L, D’Elia GM, Truini A, Niscola P, Petrucci MT (2012) Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. Support Care Cancer 20:2621–2626PubMedCrossRef

24.

Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD 3rd, Kugler JW, Hoff KL, Reddy PS, Rowland KM Jr., Riepl M, Christensen B, Loprinzi CL (2010) A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer

25.

Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, Hopkins JO, Morrow GR (2014) A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer

26.

Storey LAC, Scott AC, Boyle D, Green L, Jones AP, Fallon MT (2010) Treatment of chemotherapy-induced peripheral neuropathy (CIPN) with topical menthol: a phase I study. J Clin Oncol 28(15s) (supple;abstr 9129)

27.

Gedlicka C, Kornek GV, Schmid K, Scheithauer W (2003) Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol 14:339–340PubMedCrossRef

28.

Gedlicka C, Scheithauer W, Schull B, Kornek GV (2002) Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 20:3359–3361PubMedCrossRef

29.

Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, Gianni L (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746–1750PubMedCrossRef

30.

Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crino L (2005) A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 91:135–138PubMed

31.

Sun Y (2012) A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine (ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN). J Clin Oncol 30 (suppl; abstr 9017)

32.

Ray WA, Meredith S, Thapa PB, Hall K, Murray KT (2004) Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 75:234–241PubMedCrossRef

33.

Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132:237–251PubMedCrossRef

34.

Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85:S3–S14PubMedCentralPubMedCrossRef

35.

Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116:109–118PubMedCrossRef

36.

Raskin J, Pritchett YL, Wang F, D’Souza DN, Waninger AL, Iyengar S, Wernicke JF (2005) A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6:346–356PubMedCrossRef

37.

Wernicke JF, Pritchett YL, D’Souza DN, Waninger A, Tran P, Iyengar S, Raskin J (2006) A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67:1411–1420PubMedCrossRef

38.

Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D (2011) Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation Neurology 76: 1758–1765

39.

O’Connor AB, Dworkin RH (2009) Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 122:S22–S32PubMedCrossRef

40.

Kadiroglu AK, Sit D, Kayabasi H, Tuzcu AK, Tasdemir N, Yilmaz ME (2008) The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 22:241–245PubMedCrossRef

41.

Rowbotham MC, Goli V, Kunz NR, Lei D (2004) Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110:697–706PubMedCrossRef

42.

Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS (2003) Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 60:1284–1289PubMedCrossRef

43.

Durand JP, Brezault C, Goldwasser F (2003) Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs 14:423–425PubMedCrossRef

44.

Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23:200–205PubMedCrossRef

45.

Saarto T, Wiffen PJ (2007) Antidepressants for neuropathic pain. Cochrane Database Syst Rev CD005454

46.

Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280:1831–1836PubMedCrossRef

47.

Serpell MG (2002) Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 99:557–566PubMedCrossRef

48.

Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P (2010) A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 49:661–669PubMedCrossRef

49.

Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L (2008) Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 8:33PubMedCentralPubMedCrossRef

50.

Freeman R, Durso-Decruz E, Emir B (2008) Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 31:1448–1454PubMedCentralPubMedCrossRef

51.

Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6:253–260PubMedCrossRef

52.

Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr (2008) Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 12:203–213PubMedCrossRef

53.

Tsavaris N, Kopterides P, Kosmas C, Efthymiou A, Skopelitis H, Dimitrakopoulos A, Pagouni E, Pikazis D, Zis PV, Koufos C (2008) Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med 9:1209–1216PubMedCrossRef

54.

Leach MJ, Marden CM, Miller AA (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 27:490–497PubMedCrossRef

55.

Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A (2001) Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 57:505–509PubMedCrossRef

56.

Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, Baird BJ, Barrett P, Hammer AE (2003) Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 60:1508–1514PubMedCrossRef

57.

Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K (2000) A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 54:2115–2119PubMedCrossRef

58.

Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS (2001) Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 56:184–190PubMedCrossRef

59.

Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS (2002) Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 96:375–383PubMedCrossRef

60.

McCleane G (1999) 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial. Pain 83:105PubMedCrossRef

61.

Silver M, Blum D, Grainger J, Hammer AE, Quessy S (2007) Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage 34:446–454PubMedCrossRef

62.

Vinik AI, Tuchman M, Safirstein B, Corder C, Kirby L, Wilks K, Quessy S, Blum D, Grainger J, White J, Silver M (2007) Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 128:169–179PubMedCrossRef

63.

Wiffen PJ, Derry S, Moore RA (2011) Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev CD006044

64.

Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, Royall RM, Max MB (2002) Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 59:1015–1021PubMedCrossRef

65.

Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D (2003) Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 348:1223–1232PubMedCrossRef

66.

Gimbel JS, Richards P, Portenoy RK (2003) Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60:927–934PubMedCrossRef

67.

Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J (2003) Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105:71–78PubMedCrossRef

68.

Franek M, Vaculin S, Rokyta R (2004) GABA(B) receptor agonist baclofen has non-specific antinociceptive effect in the model of peripheral neuropathy in the rat. Physiol Res 53:351–355PubMed

69.

Gammaitoni A, Gallagher RM, Welz-Bosna M (2000) Topical ketamine gel: possible role in treating neuropathic pain. Pain Med 1:97–100PubMedCrossRef

70.

Lynch ME, Clark AJ, Sawynok J (2003) A pilot study examining topical amitriptyline, ketamine, and a combination of both in the treatment of neuropathic pain. Clin J Pain 19:323–328PubMedCrossRef

71.

Lynch ME, Clark AJ, Sawynok J, Sullivan MJ (2005) Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology 103:140–146PubMedCrossRef

72.

Lynch ME, Clark AJ, Sawynok J, Sullivan MJ (2005) Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J Pain 6:644–649PubMedCrossRef

73.

Proudfoot CJ, Garry EM, Cottrell DF, Rosie R, Anderson H, Robertson DC, Fleetwood-Walker SM, Mitchell R (2006) Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr Biol 16:1591–1605PubMedCrossRef

74.

Davies SJ, Harding LM, Baranowski AP (2002) A novel treatment of postherpetic neuralgia using peppermint oil. Clin J Pain 18:200–202PubMedCrossRef

75.

Wasner G, Naleschinski D, Binder A, Schattschneider J, McLachlan EM, Baron R (2008) The effect of menthol on cold allodynia in patients with neuropathic pain. Pain Med 9:354–358PubMedCrossRef

76.

Colvin LA, Johnson PR, Mitchell R, Fleetwood-Walker SM, Fallon M (2008) From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. J Clin Oncol 26:4519–4520PubMedCrossRef

77.

Storey DJ, Colvin LA, Mackean MJ, Mitchell R, Fleetwood-Walker SM, Fallon MT (2010) Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery. J Pain Symptom Manage 39:e2–e4PubMedCrossRef

78.

Storey DJ, Boyle LA, Scott D et al (2011) Topical menthol: a novel intervention that improved chemotherapy induced peripheral neuropathy (CIPN) related pain and physical function. Support Care Cancer 10:S158

79.

Bley KR (2004) Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs 13:1445–1456PubMedCrossRef

80.

Derry S, Moore RA (2012) Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 9: CD010111

81.

Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P Jr, Rauck R, Tobias J, Group N-CS (2008) NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 7:1106–1112PubMedCrossRef

82.

Simpson DM, Brown S, Tobias J, Group N-CS (2008) Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70:2305–2313PubMedCrossRef

83.

Derry S, Sven-Rice A, Cole P, Tan T, Moore RA (2013) Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2: CD007393

84.

Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler H, Low PA (1995) Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18:1160–1167PubMedCrossRef

85.

Ziegler D, Nowak H, Kempler P, Vargha P, Low PA (2004) Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 21:114–121PubMedCrossRef

86.

Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R (2006) Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29:2365–2370PubMedCrossRef

87.

Guo YPL, Forman A, Dakhil S R, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fish M (2011) A randomized, double-blinded, placebo-controlled trial of oral alpha lipoic acid to prevent platinum-induced polyneuropathy. J Clin Oncol 29

88.

Scafidi S, Fiskum G, Lindauer SL, Bamford P, Shi D, Hopkins I, McKenna MC (2010) Metabolism of acetyl-L-carnitine for energy and neurotransmitter synthesis in the immature rat brain. J Neurochem 114:820–831PubMedCrossRef

89.

Chiechio S, Copani A, Gereau RW, Nicoletti F (2007) Acetyl-L-carnitine in neuropathic pain: experimental data CNS. Drugs 21(Suppl 1):31–38, discussion 45–36

90.

De Grandis D (2007) Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review CNS. Drugs 21(Suppl 1):39–43, discussion 45–36

91.

Evans JD, Jacobs TF, Evans EW (2008) Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother 42:1686–1691PubMedCrossRef

92.

Sima AA (2007) Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data CNS. Drugs 21(Suppl 1):13–23, discussion 45–16

93.

Sima AA, Calvani M, Mehra M, Amato A (2005) Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 28:89–94PubMedCrossRef

94.

Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31:2627–2633PubMedCrossRef

95.

Abuaisha BB, Costanzi JB, Boulton AJ (1998) Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin Pract 39:115–121PubMedCrossRef

96.

Jiang H, Shi K, Li X, Zhou W, Cao Y (2006) Clinical study on the wrist-ankle acupuncture treatment for 30 cases of diabetic peripheral neuritis. J Tradit Chin Med 26:8–12PubMed

97.

Tong Y, Guo H, Han B (2010) Fifteen-day acupuncture treatment relieves diabetic peripheral neuropathy. J Acupunct Meridian Stud 3:95–103PubMedCrossRef

98.

Wong R, Sagar S (2006) Acupuncture treatment for chemotherapy-induced peripheral neuropathy–a case series. Acupunct Med 24:87–91PubMedCrossRef

99.

Donald GK, Tobin I, Stringer J (2011) Evaluation of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Acupunct Med 29:230–233PubMedCrossRef

100.

Schroeder S, Meyer-Hamme G, Epplee S (2012) Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med 30:4–7PubMedCrossRef

101.

Xu WR, Hua BJ, Hou W, Bao YJ (2010) Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs. Zhongguo Zhen Jiu 30:457–460PubMed

102.

Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ (2012) Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manage 43:87–95PubMedCrossRef

103.

Campbell (2013) A randomized, double-blind study of “Scrambler” therapy versus sham for painful chemotherapy-induced peripheral neuropathy (CIPN). J Clin Oncol 31: suppl; abstr 9635

104.

Coyne PJ, Wan W, Dodson P, Swainey C, Smith TJ (2013) A trial of Scrambler therapy in the treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral neuropathy. J Pain Palliat Care Pharmacother 27:359–364PubMedCrossRef

105.

Marineo G (2003) Untreatable pain resulting from abdominal cancer: new hope from biophysics? Jop 4:1–10PubMed

106.

Ricci M, Pirotti S, Scarpi E, Burgio M, Maltoni M, Sansoni E, Amadori D (2012) Managing chronic pain: results from an open-label study using MC5-A Calmare(R) device. Support Care Cancer 20:405–412PubMedCrossRef

107.

Sabato AF, Marineo G, Gatti A (2005) Scrambler therapy. Minerva Anestesiol 71:479–482PubMed

108.

Smith TJ, Coyne PJ, Parker GL, Dodson P, Ramakrishnan V (2010) Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare(R)) for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage 40:883–891PubMedCrossRef

109.

Jin DM, Xu Y, Geng DF, Yan TB (2010) Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 89:10–15PubMedCrossRef

110.

Pieber K, Herceg M, Paternostro-Sluga T (2010) Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. J Rehabil Med 42:289–295PubMedCrossRef

111.

White CM, Pritchard J, Turner-Stokes L (2004) Exercise for people with peripheral neuropathy. Cochrane Database Syst Rev CD003904

112.

Dixit S, Maiya A, Shastry B (2013) Effect of aerobic exercise on quality of life in population with diabetic peripheral neuropathy in type 2 diabetes: a single blind, randomized controlled trial. Qual Life Res

113.

Kruse RL, Lemaster JW, Madsen RW (2010) Fall and balance outcomes after an intervention to promote leg strength, balance, and walking in people with diabetic peripheral neuropathy: “feet first” randomized controlled trial. Phys Ther 90:1568–1579PubMedCrossRef

114.

Henke CC, Cabri J, Fricke L, Pankow W, Kandilakis G, Feyer PC, de Wit M (2014) Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV. Support Care Cancer 22:95–101PubMedCrossRef

115.

Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25:257–264PubMedCrossRef

Titel: Management options for established chemotherapy-induced peripheral neuropathy
verfasst von: Deirdre R. Pachman
James C. Watson
Maryam B. Lustberg
Nina D. Wagner-Johnston
Alexandre Chan
Larry Broadfield
Yin Ting Cheung
Christopher Steer
Dawn J. Storey
Kavita D. Chandwani
Judith Paice
Pascal Jean-Pierre
Jeong Oh
Jayesh Kamath
Marie Fallon
Herwig Strik
Susanne Koeppen
Charles L. Loprinzi
Publikationsdatum: 01.08.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 8/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2289-x

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Management options for established chemotherapy-induced peripheral neuropathy

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin’s lymphoma

Efficacy of an internet-based cognitive-behavioral intervention for long-term survivors of pediatric cancer: a pilot study

A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia

Use of and spending on supportive care medications among Medicare beneficiaries with cancer

Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy

Erratum to: Positive changes following cancer: posttraumatic growth in the context of other factors in patients with cancer

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie